US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,379.06

+4.600.33%

Number of Gainers:9

Number of Losers:9

Number of Flat:1

PE:- -

High:1,392.07

Open:1,378.91

Low:1,377.90

Close:1,374.47

Loading ...

Gilead Sciences: to Provide Lenacapavir to 2 Mln People Over 3 Years in Countries Supported by Global Fund, at No Profit to Gilead

THOMSON REUTERS

Gilead Sciences: Agreement With Global Fund to Accelerate Access to Lenacapavir for Hiv Prevention in Low-Income Countries

THOMSON REUTERS

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

Inovio initiated with an Overweight at Piper Sandler

Inovio Pharmaceuticals Inc : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $5

THOMSON REUTERS

DexCom Is Doubling Down on Its 'Mistake.' Why It's Time to Buy the Stock. -- Barrons.com

Pantera Minerals Sells Smackover Lithium Project for A$40 Million

Bernstein Remains a Hold on Moderna (MRNA)

‘Rare Buy Signal’ Sparks Reversal Hopes in AstraZeneca Stock (AZN)

Positive Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and FDA Approval

Bayhorse Silver Addresses Insider Disclosure Errors Amidst COVID-19 Challenges

Johnson & Johnson Files Initial Statement of Beneficial Ownership for Director Daniel E. Pinto

Press Release: Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio

Moderna Stock Is Climbing. It Has Been a Tumultuous Few Days for Pharma. -- Barrons.com

Bullish flow in Moderna with shares up 9.35%

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live

Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs

MT Newswires Live

Aptos max buy opportunity? Why $3.65 support could launch a 250% run

BUZZ-Moderna shares jump, analysts cite U.S. HHS lawsuit

Pfizer’s Abrocitinib Study: A Potential Game-Changer for Atopic Dermatitis Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1379.0648,"timestamp":1752868799999,"preClose":1374.4666,"halted":0,"volume":95962727,"delay":0,"changeRate":0.003345,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":4.598267,"latestTime":"07-18 16:00:00 EDT","open":1378.9058,"high":1392.0709,"low":1377.9001,"amount":6205677126.969449,"amplitude":0.01031,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.647019,"peRate":21.146563,"turnoverRate":0.006269,"increases":9,"decrements":9,"flats":1,"marketCap":1137445199268.5,"floatMarketCap":1116746960372.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1392.0709,"amplitude":0.01031,"preClose":1374.4666,"low":1377.9001,"pbRate":"3.647019","latestPrice":1379.0648,"volume":95962727,"delay":0,"open":1378.9058,"prevYearClose":1274.8187,"prevWeekClose":1397.679,"prevMonthClose":1377.5769,"prevQuarterClose":1377.5769,"fiveDayClose":1397.679,"twentyDayClose":1359.4229,"sixtyDayClose":1350.4775,"secType":"PLATE","market":"US","turnoverRate":0.006269,"peRate":21.146563,"marketCap":1137445199268.5,"floatMarketCap":1116746960372.5,"timestamp":1752868799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":9,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550632836","title":"Gilead Sciences: to Provide Lenacapavir to 2 Mln People Over 3 Years in Countries Supported by Global Fund, at No Profit to Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2550632836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550632836?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:00","pubTimestamp":1752062400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nP8N3JT0KN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B7SZLL34.SGD","SG9999015945.SGD","LU1674673428.USD","LU1778281490.HKD","LU1066051498.USD","LU1571399168.USD","GILD","BK4585","LU1839511570.USD","SG9999015986.USD","LU1066053197.SGD","LU0320765992.SGD","IE00BSNM7G36.USD","BK4568","LU2089984988.USD","BK4583","LU2324357040.USD","BK4588","LU2087621335.USD","LU1674673691.USD","LU0823416689.USD","LU0058720904.USD","BK4566","BK4139","LU0234570918.USD","BK4578","LU1585245621.USD","SG9999015978.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4550","BK4532","LU0109394709.USD","SG9999015952.SGD","LU0889565916.HKD","IE00B3T34201.USD","LU0289739699.SGD","LU1430594728.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2550328596","title":"Gilead Sciences: Agreement With Global Fund to Accelerate Access to Lenacapavir for Hiv Prevention in Low-Income Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2550328596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550328596?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:00","pubTimestamp":1752062400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nP8N3JT0KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1674673428.USD","LU1066051498.USD","LU0289739699.SGD","BK4532","SG9999015945.SGD","BK4550","LU1571399168.USD","LU0320765992.SGD","BK4583","IE00BSNM7G36.USD","GILD","LU1430594728.SGD","LU1585245621.USD","BK4566","LU0058720904.USD","IE00BZ1G4Q59.USD","SG9999015978.USD","LU1674673691.USD","LU2089984988.USD","LU0234570918.USD","IE00BKVL7J92.USD","BK4568","BK4578","LU1066053197.SGD","LU1839511570.USD","LU2087621335.USD","BK4139","LU2468319806.SGD","BK4585","LU2324357040.USD","LU0109394709.USD","IE00B3T34201.USD","BK4588","LU0889565916.HKD","LU1778281490.HKD","SG9999015952.SGD","IE00B19Z3581.USD","LU0823416689.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","SG9999015986.USD"],"gpt_icon":0},{"id":"2550631821","title":"Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2550631821","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550631821?lang=en_us&edition=fundamental","pubTime":"2025-07-09 18:59","pubTimestamp":1752058740,"startTime":"0","endTime":"0","summary":"1059 GMT - The tariff of up to 200% the U.S. is set to impose on pharmaceuticals could be a significant blow to the sector in the long term, Barclays analysts say in a research note. A 200% tariff would inflate production costs, compress profit margins and risk supply chain disruptions, the analysts say. This would likely lead to drug shortages and higher prices for U.S. consumers, they add. Meanwhile, the transition period of up to a year and a half companies would be given before tariffs come into effect could be seen as positive for the sector, Barclays adds. Shares in Danish drugmaker Novo Nordisk fall 1.1%. France's Sanofi, the U.K.'s AstraZeneca and Swiss pharmaceutical giant Novartis are all down around 0.2%. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","IE00BKVL7J92.USD","LU2417539215.USD","LU0208291251.USD","IE00BZ1G4Q59.USD","LU0070302665.USD","IE0002141913.USD","LU0320765489.SGD","IE0009355771.USD","LU1829250122.USD","BK4578","NVS","LU0211331839.USD","LU0109394709.USD","LU2462157665.USD","LU0154236417.USD","LU0889565916.HKD","LU0320765992.SGD","BK4599","LU1093756168.USD","LU2236285917.USD","BK4568","BK4585","BK4532","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","AZN","SNY","NVO","BK4007","BK4588","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1093756325.SGD","IE00BJT1NW94.SGD","LU2456880835.USD"],"gpt_icon":1},{"id":"2550638046","title":"Inovio initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2550638046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550638046?lang=en_us&edition=fundamental","pubTime":"2025-07-09 17:25","pubTimestamp":1752053108,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio (INO) with an Overweight rating and $5 price target The company is is developing...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inovio-initiated-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inovio-initiated-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","INO","BK4568","BK4139"],"gpt_icon":0},{"id":"2550768157","title":"Inovio Pharmaceuticals Inc : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2550768157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550768157?lang=en_us&edition=fundamental","pubTime":"2025-07-09 16:16","pubTimestamp":1752048992,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nFWN3T60BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","INO","BK4583","BK4139"],"gpt_icon":0},{"id":"2550502420","title":"DexCom Is Doubling Down on Its 'Mistake.' Why It's Time to Buy the Stock. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2550502420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550502420?lang=en_us&edition=fundamental","pubTime":"2025-07-09 13:30","pubTimestamp":1752039000,"startTime":"0","endTime":"0","summary":"Sometimes the best way to fix a mistake is to double down on it -- and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It's a decision that should pay off handsomely for shareholders.DexCom made a costly mistake last year. The San Diego--based maker of glucose monitoring devices for people suffering from diabetes decided to shift its focus away from patients with Type 1 -- which often develops in childhood -- to the larger Type 2 market of people who generally develop it later in life. Unfortunately, DexCom's focus changed so much that its Type 1 sales shriveled up. As a result, the company was forced to reduce 2024 sales guidance by $200 million last July, to about $4 billion. Shares of DexCom tumbled 41%, to $64 on July 26, the worst day in the stock's 20-year history.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00BQXX3C00.GBP","LU0320765489.SGD","LU1923622614.USD","BK4534","LU2433249047.HKD","LU0265550359.USD","SG9999002232.USD","IE0002141913.USD","LU2468319806.SGD","LU1721429402.USD","BK4592","IE00BFXG1179.USD","IE00BMPRXN33.USD","LU0158827948.USD","LU0162691827.USD","BK4551","IE00BQXX3D17.EUR","LU0211326755.USD","LU2133065610.SGD","BK4082","LU0314106906.USD","LU2112291526.USD","LU2028103732.USD","LU1116320737.USD","BK4588","LU1691799644.USD","MDT","LU2089283258.USD","LU0266013472.USD","BK4568","LU0170899867.USD","LU0070302665.USD","IE00B3T34201.USD","LU0234572021.USD","LU1023059063.AUD","LU1983299246.USD","DXCM","LU1116320901.HKD","LU1989764664.SGD","LU2089284900.SGD","BK4581","LU2089984988.USD","LU0265550946.USD","LU0868494617.USD","ABT","BK4585","IE00BMPRXR70.SGD","LU1291159041.SGD","LU0211326839.USD"],"gpt_icon":0},{"id":"2550228572","title":"Pantera Minerals Sells Smackover Lithium Project for A$40 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2550228572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550228572?lang=en_us&edition=fundamental","pubTime":"2025-07-09 08:57","pubTimestamp":1752022665,"startTime":"0","endTime":"0","summary":"Pantera Minerals Ltd. ( ($AU:PFE) ) has issued an update. Pantera Minerals Ltd. has entered into a binding agreement to sell its Smackover lithium ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pantera-minerals-sells-smackover-lithium-project-for-a40-million?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pantera-minerals-sells-smackover-lithium-project-for-a40-million?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999011175.SGD","BK4007","LU0225284248.USD","LU1057294990.SGD","BK4109","LU0122379950.USD","BK4581","LU0225771236.USD","BK4533","SG9999001176.USD","SG9999002232.USD","IE00B19Z3581.USD","LU0321505868.SGD","LU1894683264.USD","LU0234572021.USD","LU0321505439.SGD","BK4599","IE00BLSP4452.SGD","LU1894683348.USD","BK4588","MTX","SG9999002224.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066051498.USD","PFE","BK4534","IE00BLSP4239.USD","LU0868494617.USD","LU1023059063.AUD","LU0058720904.USD","LU0289739699.SGD","BK4550","LU1066053197.SGD","SG9999001176.SGD","SG9999013999.USD","BK4568","LU1883839398.USD","BK4592","SG9999003800.SGD","IE0002270589.USD","LU0456855351.SGD","LU0985481810.HKD","LU0170899867.USD","LU0306807586.USD","LU0306806265.USD","BK4585","IE00BBT3K403.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2550723675","title":"Bernstein Remains a Hold on Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550723675","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550723675?lang=en_us&edition=fundamental","pubTime":"2025-07-09 08:35","pubTimestamp":1752021315,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna. The company’s shares closed yesterday at $32.54....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-moderna-mrna-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-moderna-mrna-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4551","BK4548","BK4585","BK4139","BK4568","BK4588","BK4501","BK4534","BK4532","MRNA"],"gpt_icon":0},{"id":"2550723505","title":"‘Rare Buy Signal’ Sparks Reversal Hopes in AstraZeneca Stock (AZN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550723505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550723505?lang=en_us&edition=fundamental","pubTime":"2025-07-09 08:33","pubTimestamp":1752021180,"startTime":"0","endTime":"0","summary":"Despite a rough outing in the market to start off the week, multinational pharmaceutical and biotechnology giant AstraZeneca ($AZN) managed to move...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/rare-buy-signal-sparks-reversal-hopes-in-astrazeneca-stock-azn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/rare-buy-signal-sparks-reversal-hopes-in-astrazeneca-stock-azn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","LU1829250122.USD","LU2456880835.USD","LU0889565916.HKD","BK4568","BK4585","LU2236285917.USD","LU0320765992.SGD","AZN","LU2417539215.USD","LU0109394709.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2550574610","title":"Positive Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2550574610","media":"TIPRANKS","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550574610?lang=en_us&edition=fundamental","pubTime":"2025-07-09 08:16","pubTimestamp":1752020213,"startTime":"0","endTime":"0","summary":"Analyst Courtney Breen of Bernstein maintained a Buy rating on Gilead Sciences, retaining the price target of $120.00. Courtney Breen has given his...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-gilead-sciences-driven-by-yeztugos-market-potential-and-fda-approval-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-gilead-sciences-driven-by-yeztugos-market-potential-and-fda-approval-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","IE00B19Z3581.USD","LU0823416689.USD","BK4550","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1571399168.USD","BK4578","LU1778281490.HKD","IE00B7SZLL34.SGD","LU0320765992.SGD","SG9999015945.SGD","BK4139","BK4568","LU1585245621.USD","LU2324357040.USD","SG9999015978.USD","BK4532","SG9999015952.SGD","IE00B3T34201.USD","LU0058720904.USD","LU0289739699.SGD","LU1674673691.USD","LU0889565916.HKD","LU1674673428.USD","BK4585","LU0109394709.USD","LU1066051498.USD","BK4583","GILD","LU1430594728.SGD","LU1066053197.SGD","LU1839511570.USD","IE00BKVL7J92.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","SG9999015986.USD","LU0234570918.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU2087621335.USD","BK4588"],"gpt_icon":0},{"id":"2550579104","title":"Bayhorse Silver Addresses Insider Disclosure Errors Amidst COVID-19 Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2550579104","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550579104?lang=en_us&edition=fundamental","pubTime":"2025-07-09 07:12","pubTimestamp":1752016361,"startTime":"0","endTime":"0","summary":"Bayhorse Silver ( ($TSE:BHS) ) has shared an announcement. Bayhorse Silver Inc. has clarified errors in its insider holdings disclosures following ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayhorse-silver-addresses-insider-disclosure-errors-amidst-covid-19-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayhorse-silver-addresses-insider-disclosure-errors-amidst-covid-19-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4535","BK4568","BK4585","BK4551","BK4588","BNTX","BK4548"],"gpt_icon":0},{"id":"2550575464","title":"Johnson & Johnson Files Initial Statement of Beneficial Ownership for Director Daniel E. Pinto","url":"https://stock-news.laohu8.com/highlight/detail?id=2550575464","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550575464?lang=en_us&edition=fundamental","pubTime":"2025-07-09 05:32","pubTimestamp":1752010320,"startTime":"0","endTime":"0","summary":"Johnson & Johnson has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing lists Daniel E. Pinto as the beneficial owner, noting his role as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL100vjz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","IE0034235303.USD","LU0234570918.USD","LU0985320562.USD","LU2505996681.GBP","IE00B42XCP33.USD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","BK4592","LU2112291526.USD","LU0640476718.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","IE00B3T34201.USD","LU0320765646.SGD","LU2602419157.SGD","LU0345770308.USD","LU1244550494.USD","LU2592432038.USD","LU1674673428.USD","LU2089984988.USD","LU0058720904.USD","LU1244550221.USD","IE00BVYPNV92.GBP","LU0289739699.SGD","LU1032466523.USD","LU1585245621.USD","LU1066051811.HKD","LU2133065610.SGD","LU1066051225.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0912757837.SGD","LU1261432733.SGD","IE00B19Z3581.USD","IE0009355771.USD","IE00B7SZLL34.SGD","IE00BGHQF631.EUR","BK4504","SG9999002232.USD","IE00B3PB1722.GBP","IE00BLSP4239.USD","BK4588","IE0002141913.USD","IE000M9KFDE8.USD","LU0098860793.USD","BK4568","IE0002270589.USD","LU1894683264.USD","JNJ"],"gpt_icon":0},{"id":"2550575695","title":"Press Release: Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2550575695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550575695?lang=en_us&edition=fundamental","pubTime":"2025-07-09 05:18","pubTimestamp":1752009480,"startTime":"0","endTime":"0","summary":"-- Oversubscribed round was led by Future Ventures, and included NFX, BOLD. Capital Partners, Kendall Capital Partners, Amplify Bio, Base4 Capital. Pfizer, SVP of Research at Merck, and CEO of the Bill & Melinda Gates. Medical Research Institute, joins the Board of Directors. SOUTH SAN FRANCISCO, Calif., July 8, 2025 /PRNewswire/ -- Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed $45 million Series A financing. The round was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, SpaceX, Prellis Biologics, Cambrian Bio, and others which in aggregate represent $1.4 trillion of value creation. The round includes participation from NFX, BOLD Capital Partners, Base4 Capital, Kendall Capital Partners, Amplify Bio, and other investors. Existing insiders increased their ownership in the round.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4599","LU0225284248.USD","LU1894683348.USD","R","BK4604","IE00BLSP4239.USD","BK4592","LU0289739699.SGD","LU0321505868.SGD","LU1883839398.USD","TM","LU1066053197.SGD","BK4568","SG9999002224.SGD","LU0234572021.USD","SG9999011175.SGD","LU0306806265.USD","IE00BBT3K403.USD","SG9999003800.SGD","IE000M9KFDE8.USD","UVV","SG9999013999.USD","BK4007","IE00BLSP4452.SGD","LU0122379950.USD","LU0306807586.USD","LU0321505439.SGD","BK4555","BK4581","LU1023059063.AUD","IE00B19Z3581.USD","BK4232","SGXZ57979304.SGD","BK4533","LU1066051498.USD","BK4534","LU1894683264.USD","03160","SG9999001176.USD","LU0058720904.USD","SG9999002232.USD","BK4588","SG9999001176.SGD","BK4099","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0456855351.SGD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2550520340","title":"Moderna Stock Is Climbing. It Has Been a Tumultuous Few Days for Pharma. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2550520340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550520340?lang=en_us&edition=fundamental","pubTime":"2025-07-09 02:51","pubTimestamp":1752000660,"startTime":"0","endTime":"0","summary":"Moderna stock surged on Tuesday amid what has been a lively past few days for the pharmaceutical industry.The tumultuous period kicked off when President Donald Trump's massive tax-and-spending bill was signed into law Friday. The legislation includes a provision that allows companies to immediately expense their U.S.-based research and development. The change allows for quicker deductions in a way that improves near-term cashflows.Moderna's cash flow issues are more immediate than those of its peers, so the new provision could have a greater impact on operations. Moderna saw revenue peak during the pandemic, as the maker of one of three FDA-approved Covid-19 vaccines, but the drugmaker has struggled since then amid declining demand.The stock has seen elevated levels of short interest in recent months. As of mid-June, Moderna was the second most-shorted stock in the S&P 500 index, with 18.6% of shares sold short as a percentage of float. These levels are down from 19.27% in May, when M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"36aa7b3b0e5d12a0b0767a4494ad1a18","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4532","BK4139","BK4588","BK4535","BK4548","BK4551","BNTX","BK4568","BK4533","BK4534","BK4501","NVAX","MRNA","BK4547"],"gpt_icon":1},{"id":"2550252096","title":"Bullish flow in Moderna with shares up 9.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550252096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550252096?lang=en_us&edition=fundamental","pubTime":"2025-07-09 02:50","pubTimestamp":1752000617,"startTime":"0","endTime":"0","summary":"Bullish flow in Moderna (MRNA), with shares up $2.79, or 9.35%, near $32.70. Options volume nearly triple the daily average with 227k contracts tra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bullish-flow-in-moderna-with-shares-up-9-35-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bullish-flow-in-moderna-with-shares-up-9-35-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4533","BK4568","BK4585","BK4551","BK4501","BK4588","BK4532","BK4548","BK4534","MRNA"],"gpt_icon":0},{"id":"2550522050","title":"Sector Update: Health Care Stocks Advance in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2550522050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550522050?lang=en_us&edition=fundamental","pubTime":"2025-07-09 01:57","pubTimestamp":1751997449,"startTime":"0","endTime":"0","summary":"Health care stocks rose Tuesday afternoon with the NYSE Health Care Index gaining 0.3% and the Health Care Select Sector SPDR Fund  adding 0.5%.The iShares Biotechnology ETF  climbed 1.3%.In corporate news, Recursion Pharmaceuticals  shares jumped 11% after the company gained full rights to REV102, a drug candidate for hypophosphatasia, after acquiring Rallybio's  interest in the program. Rallybio surged 43%.Pfizer  Chief Corporate Officer Sally Susman will leave the company at the end of the year. Pfizer shares rose 1.1%.ProKidney  shares soared more than sixfold after the company said its investigational therapy rilparencel stabilized kidney function in a group of patients with chronic kidney disease and diabetes who received two injections about three months apart in a phase 2 trial, replicating the dosing regimen of its ongoing phase 3 study.Maze Therapeutics'  development strategy using genetic validation is seen as promising in terms of its target identification strategy and appl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0321505868.SGD","LU1894683264.USD","LU1883839398.USD","LU1023059063.AUD","BK4534","PFE.AU","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3581.USD","SGXZ57979304.SGD","BK4568","BK4539","LU0170899867.USD","BK4592","SG9999001176.USD","RXRX","LU0868494617.USD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1066053197.SGD","SG9999002232.USD","MAZE","BK4007","LU0985481810.HKD","RLYB","LU0058720904.USD","BK4581","IBB","IE0002270589.USD","XLV","PROK","BK4139","SG9999001176.SGD","SG9999011175.SGD","BK4550","BK4533","SG9999002224.SGD","SG9999003800.SGD","BK4588","LU1066051498.USD","LU0225771236.USD","LU1894683348.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU0456855351.SGD","LU0306806265.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2550522798","title":"Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2550522798","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550522798?lang=en_us&edition=fundamental","pubTime":"2025-07-09 01:47","pubTimestamp":1751996854,"startTime":"0","endTime":"0","summary":"Price: 25.49, Change: +0.25, Percent Change: +0.99","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1989772923.USD","LU0965509101.SGD","LU1935042991.SGD","BK4599","BK4007","PFE","SG9999014567.USD","LU1221951046.USD","LU0203347892.USD","IE0034235303.USD","IE00BLSP4452.SGD","LU0868494617.USD","LU0238689110.USD","LU1066051225.USD","LU1506573853.SGD","LU1914381329.SGD","LU1093756168.USD","SG9999013999.USD","IE00BKVL7J92.USD","LU0965508806.USD","IE00B3T34201.USD","LU1974910355.USD","LU0306807586.USD","BK4568","GSK","LU0306806265.USD","LU1093756325.SGD","LU0170899867.USD","LU2505996509.AUD","LU2324357040.USD","MRK","SG9999015341.SGD","NVO","JNJ","BK4559","IE00BN8TJ469.HKD","BK4504","LU2129689514.USD","LU0889566641.SGD","LU1244550494.USD","NVS","LU0266013472.USD","GSK.UK","LU1917777945.USD","LU1032955483.USD","LU2361045086.USD","LU0345769631.USD","LU1883839398.USD","BK4592","LU0321505439.SGD"],"gpt_icon":0},{"id":"2550522269","title":"Aptos max buy opportunity? Why $3.65 support could launch a 250% run","url":"https://stock-news.laohu8.com/highlight/detail?id=2550522269","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550522269?lang=en_us&edition=fundamental","pubTime":"2025-07-09 01:28","pubTimestamp":1751995687,"startTime":"0","endTime":"0","summary":"Aptos is trading at the bottom of a multi-month range. With a potential rounded bottom forming and confluence at $14, the current support zone offers a high-reward setup with 250% upside.Aptos  is currently positioned in what can only be described as a “Max Opportunity” zone—the lower boundary of a high time frame trading range that has held firm for months. Historically, this zone has served as a launchpad for rallies toward the range high and now presents a compelling long setup for both swing traders and long-term investors. The price structure hints at accumulation, and attention is now focused on whether bullish expansion can emerge from this technically significant area.Major Support at $3.65: Long-term range low aligning with the value area low.Rounded Bottom Structure Forming: Accumulation pattern supports a reversal narrative.Upside Target at $14: 0.618 Fibonacci and high time frame resistance aligned, representing a potential 250% rally.Trump Media’s ‘Truth Social Bitcoin and","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/aptos-max-buy-opportunity-why-3-65-support-could-launch-a-250-run/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["APT","APT.AU","BK4086","APT.USD.HKCC","BK4568","APT.USD.CC"],"gpt_icon":0},{"id":"2550032521","title":"BUZZ-Moderna shares jump, analysts cite U.S. HHS lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2550032521","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550032521?lang=en_us&edition=fundamental","pubTime":"2025-07-09 00:24","pubTimestamp":1751991879,"startTime":"0","endTime":"0","summary":"BUZZ-Moderna shares jump, analysts cite U.S. HHS lawsuit** Shares of vaccine maker Moderna MRNA.O up 11% at $33.20 ** On Monday, leading medical organizations filed a lawsuit against U.S. Health Secretary Robert F. Kennedy Jr. and Department of Health and Human Services, arguing that current policies on COVID-19 vaccines pose an imminent threat to public health** B. Riley Securities analyst Mayank Mamtani said the share movement likely reflects \"a reversal of peak negative investor sentiment, with now there being some near-term events, both vaccine advisory committee  and lawsuit-related.\"** Other vaccine makers like Pfizer PFE.N and Novavax NVAX.O up 1.6% and 6.7%, respectively** Mamtani cites recent late-stage study data for COVID-influenza combination and standalone flu vaccines as an additional driver for NVAX stock** Including sessions' moves, MRNA has lost 20.2% YTD, while NVAX is down 11.4%   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nL4N3T515F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","BK4599","LU0225284248.USD","IE0002270589.USD","LU1894683264.USD","BK4139","LU0234572021.USD","LU0306807586.USD","LU0321505439.SGD","LU1066053197.SGD","BK4550","BK4547","LU1883839398.USD","LU0306806265.USD","LU0122379950.USD","LU1057294990.SGD","BK4532","SG9999003800.SGD","BK4548","NVAX","LU0170899867.USD","LU0058720904.USD","MRNA","BK4592","LU0225771236.USD","LU1894683348.USD","BK4581","IE00B19Z3581.USD","BK4585","IE00BLSP4452.SGD","SG9999001176.USD","BK4534","LU0321505868.SGD","BK4551","IE00BBT3K403.USD","SG9999001176.SGD","LU0868494617.USD","BK4533","SG9999011175.SGD","SG9999013999.USD","BK4007","IE00B19Z3B42.SGD","LU0289739699.SGD","BK4501","LU0456855351.SGD","IE00BLSP4239.USD","LU0985481810.HKD","BK4568","BK4588"],"gpt_icon":1},{"id":"2550521003","title":"Pfizer’s Abrocitinib Study: A Potential Game-Changer for Atopic Dermatitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2550521003","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550521003?lang=en_us&edition=fundamental","pubTime":"2025-07-09 00:17","pubTimestamp":1751991473,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Treating Atopic Dermatitis With ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-abrocitinib-study-a-potential-game-changer-for-atopic-dermatitis-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-abrocitinib-study-a-potential-game-changer-for-atopic-dermatitis-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","BK4599","BK4533","IE000M9KFDE8.USD","SG9999002232.USD","LU0058720904.USD","BK4534","LU1894683348.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","SG9999013999.USD","LU0289739699.SGD","LU0456855351.SGD","IE0002270589.USD","LU0306806265.USD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0225284248.USD","SG9999001176.USD","SG9999001176.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0170899867.USD","BK4568","LU0985481810.HKD","LU1057294990.SGD","LU0868494617.USD","BK4581","BK4585","BK4592","IE00BLSP4239.USD","LU1066051498.USD","LU1066053197.SGD","LU0225771236.USD","LU1883839398.USD","PFE","LU1894683264.USD","SG9999011175.SGD","BK4007","BK4588","LU0321505868.SGD","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0306807586.USD","LU0122379950.USD","BK4550"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":10,"totalSize":237,"code":"91000000","status":"200"}]}}